Antituberculosis drugs and hepatotoxicity among hospitalized patients in Jos, Nigeria

International Journal of Mycobacteriology

Volumn 5, Issue 1, 2016, Pages 21-26

  Isa, Samson E ^a   Ebonyi, Augustine O ^a   Shehu, Nathan Y ^a   Idoko, Patrick ^a   Anejo Okopi, Joseph A ^a   Simji, Gomerep ^a   Odesanya, Rachael U ^a   Abah, Isaac O ^a   Jimoh, Hafsat O ^a  

^a UNIVERSITY OF JOS   (Nigeria)

Author keywords

Antituberculosis; Incidence; Nigeria; Toxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; ETHAMBUTOL; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT; ASPARTATE AMINOTRANSFERASE;

ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENDER; HEPATITIS B; HEPATITIS C; HOSPITAL PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; NIGERIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TOXIC HEPATITIS; TREATMENT DURATION; TUBERCULOSIS; BLOOD; CHEMICAL AND DRUG INDUCED LIVER INJURY; COMPLICATION; HOSPITALIZATION; LIVER; MIDDLE AGED; PATHOLOGY; STATISTICS AND NUMERICAL DATA; TUBERCULIN TEST;

ADULT; ALANINE TRANSAMINASE; ANTITUBERCULAR AGENTS; ASPARTATE AMINOTRANSFERASES; CHEMICAL AND DRUG INDUCED LIVER INJURY; COHORT STUDIES; FEMALE; HIV INFECTIONS; HOSPITALIZATION; HUMANS; INCIDENCE; LIVER; MALE; MIDDLE AGED; NIGERIA; RETROSPECTIVE STUDIES; TUBERCULIN TEST; TUBERCULOSIS;

EID: 84959093180     PISSN: 22125531     EISSN: 2212554X     Source Type: Journal    
DOI: 10.1016/j.ijmyco.2015.10.001     Document Type: Article

References (29)

1. WHO, Global tuberculosis report 2014, from <> (accessed 15.07.2015). http://www.who.int/tb/publications/global_report/en/.
2. National Tuberculosis and Leprosy Control Program-Workers Manual 2010, Federal Ministry of Health, Nigeria. fifth ed.
3. Ormerod L.P. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations of the Joint Committee of the British Thoracic Society. Thorax 1990, 45:403-408.
4. Bassey E.B., Momoh M.A., Imadiyi S.O., et al. The trend of pulmonary tuberculosis in patients seen at DOTS clinics in the Federal Capital Territory, Abuja, Nigeria. Public Health 2005, 119:405-408.
5. Tostmann A., Boeree M.J., Aarnoutse R.E., et al. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J. Gastroenterol. Hepatol. 2008, 23:192-202.
6. Wong W.M., Wu P.C., Yuen M.F., et al. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 2000, 31:201-206.
7. Ungo J.R., Jones D., Askin D., et al. Anti-TB drug-induced hepatotoxicity. The role of hepatitis C and the HIV. Am. J. Respir. Crit. Care Med. 1998, 157:1871-1876.
8. Pande J.N., Singh S.P.N., Khilnani G.C., et al. Risk factors for hepatotoxicity from anti-TB drugs: a case-control study. Thorax 1996, 51:132-136.
9. Huang Y.S., Chern H.D., Su W.J., et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 2003, 37:924-930.
10. Ozick L.A., Jacob L., Comer G.M., et al. Hepatotoxicity from isoniazid and rifampin in inner-city AIDS patients. Am. J. Gastroenterol. 1995, 90:1978-1980.
11. Gross M., Kruisselbrink T., Anderson K., et al. Distribution and concordance of N-acetyltransferase genotype and phenotype in an American population. Cancer Epidemiol. Biomarkers Prev. 1999, 8:683-692.
12. C. Tam, W. Yew, C. Leung, et al., Monitoring for hepatotoxicity during antituberculosis treatment. General recommendations. A consensus statement of the Tuberculosis Control Coordinating Committee of the Hong Kong Department of Health and the Tuberculosis Subcommittee of the Coordinating Committee in Internal Medicine of the Hospital Authority. Hong Kong, April, 2002, from (accessed 02.08.2015). .
13. Jussi J., Saukkonen D.L., Robert M.J., et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am. J. Respir. Crit. Care Med. 2006, 174:935-952.
14. Makhlouf H.A., Helmy A., Fawzy E., et al. Prospective study of antituberculous drug-induced hepatotoxicity in an area endemic for liver diseases. Hepatol. Int. 2008, 2:353-360.
15. Hassen A.A., Belachew T., Yami A., et al. Anti-tuberculosis drug induced hepatotoxicity among TB/HIV co-infected patients at Jimma University Hospital, Ethiopia: nested case-control study. PLoS One 2008, 3:e1809.
16. An H., Wu X., Wang Z., et al. The clinical characteristics of anti-tuberculosis drug induced liver injury in 2457 hospitalized patients with tuberculosis in China. Afr. J. Pharm. Pharmacol. 2013, 7:710-714.
17. Shakya R., Rao B.S., Shrestha B. Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors. Ann. Pharmacother. 2004, 38:1074-1079.
18. Xiang Y., Ma L., Wu W., et al. The incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstt1. PLoS One 2014, 9:e85905.
19. Yimer G., Ueda N., Habtewold A., et al. Pharmacogenetic and pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients. PLoS One 2011, 6:e27810.
20. Senaratne V.W., Pinidiyapathirage M.J., Perera G.A., et al. Anti-tuberculosis drug induced hepatitis - a Sri Lankan experience. Ceylon Med. J. 2006, 51:9-14.
21. Sharifzadeh M., Rasoulinejad M., Valipour F., et al. Evaluation of patient-related factors associated with causality, preventability, predictability and severity of hepatotoxicity during anti-TB treatment. Pharmacol. Res. 2005, 51:353-358.
22. Tahaoglu K., Atac G., Sevim T., et al. The management of anti-tuberculosis drug-induced hepatotoxicity. Int. J. Tuberc. Lung Dis. 2001, 5:65-69.
23. Fernandez-Villar A., Sopena B., Fernandez-Villar J., et al. The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity. Int. J. Tuberc. Lung Dis. 2004, 8:1499-1505.
24. Hussain Z., Kar P., Hussain S.A. Antituberculosis drug-induced hepatitis: risk factors, prevention and management. Indian J. Exp. Biol. 2003, 41:1226-1232.
25. Khalili H., Dashti-Khavidaki S., Rasoolinejad M., et al. Anti-tuberculosis drugs related hepatotoxicity; incidence, risk factors, pattern of changes in liver enzymes and outcome. DARU 2009, 17:163-167.
26. Marks D., Dheda K., Dawson R., et al. Adverse events to anti-TB therapy: influence of HIV and antiretroviral drugs. Int. J. STD AIDS 2009, 20:339-345.
27. Pukenyte E., Lescure F.X., Rey D., et al. Incidence of and risk factors for severe liver toxicity in HIV-infected patients on anti-TB treatment. Int. J. Tuberc. Lung Dis. 2007, 11:78-84.
28. Teleman M.D., Chee C.B., Earnest A., et al. Hepatotoxicity of tuberculosis chemotherapy under general program conditions in Singapore. Int. J. Tuberc. Lung Dis. 2002, 6:699-705.
29. Williams G.M., Iatropoulos M.J. Alteration of liver cell function and proliferation: differentiation between adaptation and toxicity. Toxicol. Pathol. 2002, 30:41-53.